ASCO 2018: Elevated Serum PD-L1 May Identify Patients With HER2–Positive Metastatic Breast Cancer Who Would Benefit From the Addition of a Checkpoint Inhibitor
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.